CTOs on the Move

Berg Pharma

www.bergpharma.com

 
Berg Pharma focuses research on understanding how alterations in metabolism relate to disease onset. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the Berg Interrogative Biology™ discovery platform that translates biological output into therapeutic candidates, Berg Pharma is well positioned for rapid commercialization of its intellectual capital.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.bergpharma.com
  • 500 Old Connecticut Path
    Framingham, MA USA 01701
  • Phone: 617.588.0083

Executives

Name Title Contact Details

Similar Companies

PharmaDerm

PharmaDerm is a Florham Park, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Millennium Laboratories

Millennium Laboratories is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Caron Products and Services

Caron Products is a provider of incubators & chambers for cell growth and product environmental testing in biological research, scale-up culture, and drug and biological QA/QC testing. Caron`s products are integral to workflows ranging from cell & gene therapy to medical device manufacturing. Caron`s expanding resources, with manufacturing facilities in both the USA and Europe, and a worldwide network of sales and service personnel aligns with the needs of the global biomedical industry.

Cellular Engineering Technologies

Cellular Engineering Technologies, Inc. is a Coralville, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diamedica

DiaMedica Inc., a development stage biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. The company`s lead clinical stage compound is DM199, a recombinant human protein known as rhKLK1, which is under phase I/II clinical trials for the treatment of Type 1 and Type 2 diabetes and associated complications. It is also developing DM204, a monoclonal antibody that is in preclinical development for the treatment of Type 2 diabetes; and DMDx, a chronic kidney disease assay to detect levels of the tissue kallikrein-1 protein in urine and to predict the rate of kidney disease progression. The company was formerly known as Diabex Inc. and changed its name to DiaMedica Inc. in February 2001. DiaMedica Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.